Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Govt. Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect

This article was originally published in The Pink Sheet Daily

Executive Summary

The development follows a relentless campaign launched over the last two years by the Indian Pharmaceutical Alliance, a powerful lobby of 17 large Indian companies.

You may also be interested in...

Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies

MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations

Not Selling Yet, Cipla Opposes Capping MNC-led Buyouts Of Indian Firms

MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction

India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments

MUMBAI - Whether increased acquisitions of large Indian companies by multinational companies presents a threat to public health is being considered by a high-level inter-ministerial group that may approve provisions that distinguish between "greenfield" and "brownfield" investments made in India by external organizations or agencies

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts